Stay updated on Pembrolizumab SBRT in TKI mRCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab SBRT in TKI mRCC Clinical Trial page.

Latest updates to the Pembrolizumab SBRT in TKI mRCC Clinical Trial page
- Check5 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3. No changes visible in the study details content.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedOnly visual styling changes were observed (header/footer and layout). The core study content, including eligibility criteria and outcomes, remains unchanged.SummaryDifference0.1%

- Check34 days agoChange DetectedRevision: v3.4.2 was added and the funding-lapse notice was removed. The change does not affect study design, eligibility criteria, endpoints, or locations.SummaryDifference0.5%

- Check41 days agoChange DetectedA site-wide notice about government funding and NIH operations was added, and the document revision was updated to v3.4.1 (replacing v3.4.0).SummaryDifference0.5%

- Check48 days agoChange DetectedUI updates: added a Show glossary option and updated QC metadata labels to 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data' with a new 'Revision: v3.4.0', while older labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check84 days agoChange DetectedThe Locations section was updated to add Alberta and Ontario locations and remove the former Alberta Locations and Ontario Locations entries, with the revision updated to v3.3.3.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab SBRT in TKI mRCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab SBRT in TKI mRCC Clinical Trial page.